Mizuho Securities analyst Vamil Divan reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) on Sunday, setting a price target of $134, which is approximately...
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) on Wednesday, setting a price target of $135, which is...
Mizuho Securities analyst Vamil Divan maintained a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) on Wednesday, setting a price target of $92, which is...
Say ‘insider trading,’ and most people will immediately think of shady market moves and dishonest salesmen, or, perhaps, Martha Stewart, who was famously convicted of...
As the earnings season comes to an end, the focus is back on pipeline updates from biotech players. Quite a few companies came out with important news this week. Biotech bigwig,...
Investors in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) need to pay close attention to the stock based on moves in the options market lately. That is because the...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,660.30 | 2,668.00 | 2,596.00 | +91.9 | +3.58% | 2.08M | ||||
| 369.79 | 375.33 | 357.19 | +18.60 | +5.30% | 33.69M | ||||
| 6.66 | 7.01 | 6.66 | -0.300 | -4.31% | 36.22K | ||||
| 195.58 | 197.00 | 192.50 | -0.36 | -0.18% | 19.57M | ||||
| 38.69 | 38.96 | 38.42 | +0.14 | +0.36% | 112.79K | ||||
| 6.94 | 7.28 | 6.76 | -0.300 | -4.14% | 11.79M | ||||
| 206.53 | 206.89 | 203.56 | -7.51 | -3.51% | 25.54M | ||||
| 2,756.30 | 2,776.20 | 2,694.00 | +89.8 | +3.37% | 1.32M | ||||
| 8.05 | 8.44 | 7.97 | -0.57 | -6.61% | 28.13M | NASDAQ | |||
| 20.01 | 20.65 | 19.75 | -0.50 | -2.44% | 728.03K | NASDAQ | |||
| 0.0029 | 0.00 | 0.00 | 0.0000 | 0.00% | 135.52M | ||||
| 28.15 | 28.21 | 27.93 | +0.14 | +0.50% | 30.23M | NYSE | |||
| 4.64 | 4.857 | 4.415 | +0.040 | +0.87% | 49.72K | ||||
| 86.22 | 86.26 | 84.74 | +1.41 | +1.66% | 834.46K | ||||
| 106.48 | 106.50 | 106.43 | 0.00 | 0.00% | 0.00 |
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. The Company also develops bispecific compounds that is designed to emulate or enhance the activity of biologics.
